Skip to main content
SpringerLink
Log in

Second generation aromatase inhibitor — 4-hydroxyandrostenedione

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

4-hydroxyandrostenedione is a steroidal, suicide substrate inhibitor of aromatase, which has been widely tested in postmenopausal breast cancer patients. It is highly specific with the only notable endocrine changes other than oestrogen suppression being a dose-related suppression of sex-hormone binding globulin when the drug is given orally (a reflection of the drug's minor androgenic activity). Intramuscular administration of 250 mg every second week is the schedule of choice. This achieves peripheral aromatase inhibition of about 85% and oestradiol suppression of about 65%. The drug is usually used second-line, after tamoxifen, with an overall response rate in unselected patients of 26%. Side-effects are minimal and consist almost entirely of local reactions at the site of injection. 4-hydroxyandrostenedione is therefore a useful new treatment option as the first selective aromatase inhibitor to have wide clinical availability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brodie AMH, Garrett WM, Hendrickson,JR, Tsai-Morris C-H, Marcotte PA, Robinson CH: Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effectsin vivo. Steroids 38:693–702, 1981

    Google Scholar 

  2. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49:1306–1312, 1989

    Google Scholar 

  3. Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, Coombes RC: An endocrine and pharmacokinetic study of 4 oral doses of Formestane in postmenopausal breast cancer patients. Eur J Cancer 28: 415–420, 1992

    Google Scholar 

  4. Dowsett M, Lloyd P: Comparison of the pharmacokinetics and pharmcodynamics of unformulated and formulated 4-hydroxyandrostenedione (CGP 32349) taken orally by healthy male volunteers. Cancer Chemother Pharmacol 27:67–71, 1990

    Google Scholar 

  5. Khubieh J, Aherne GW, Chakraborty J: Serum of the anticancer agent 4-OHA in the rat. Cancer Chemotherapy Pharm 26:330–332, 1990

    Google Scholar 

  6. Poon GK, Jarman M, Rowlands MG, Dowsett M, Firth J: Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using High-Performance Liquid Chromatography-Mass Spectrometry. J Chromatogr 565:75–88, 1991

    Google Scholar 

  7. Goss PE, Powles TJ, Dowsett M, Hutchinson G, Brodie AMH, Coombes RC: Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione — phase II report. Cancer Res 46:4823–4826, 1986

    Google Scholar 

  8. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC: Use of the aromatase inhibitors 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 47:1957–1961, 1987

    Google Scholar 

  9. Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ: The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28:1712–1716, 1992

    Google Scholar 

  10. Pickles T, Perry L, Murray P, Plowman P: 4-hydroxyandrostenedione — further clinical and extended endocrine observations. Br J Cancer 62:309–313, 1990

    Google Scholar 

  11. Coombes RC, Hughes SWM, Dowsett M: 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 28A:1941–1945, 1992

    Google Scholar 

  12. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 43:155–159, 1992

    Google Scholar 

  13. Lonning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F, Johannessen DC, Powles TJ: Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res Treat 23:57–62, 1992

    Google Scholar 

  14. Lonning PE, Kvinnsland S: Mechanism of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35:685–710, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Dept of Biochemistry, Royal Marsden Hospital, SW3 6JJ, London, UK

    M. Dowsett

  2. Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, W6 8RF, London, UK

    R. C. Coombes

Authors
  1. M. Dowsett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. C. Coombes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dowsett, M., Coombes, R.C. Second generation aromatase inhibitor — 4-hydroxyandrostenedione. Breast Cancer Res Tr 30, 81–87 (1994). https://doi.org/10.1007/BF00682742

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00682742

Key words

Search

Navigation